Cyclerion Therapeutics Profit Margin

The latest profit margin for CYCN is -353.0% as of June 2026. That compares with -56.26% in the prior-year period — down 527.5% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Cyclerion Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYCN's profit margin moved from -56.26% to -353.0% — a 527.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cyclerion Therapeutics's valuation or profitability profile.

Against Healthcare companies, CYCN currently prints -353.0% for profit margin, while the sector average sits near 14.34%. That is roughly 2560.8% below the sector mean. Large gaps often invite a closer look at Cyclerion Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Cyclerion Therapeutics converts resources into returns. At -353.0%, CYCN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -56.26% in the prior-year period — down 527.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CYCN's profit margin (-353.0%), review year-over-year change from -56.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.